Protein kinase‐dependent oxidative regulation of the cardiac Na+–K+ pump: evidence from in vivo and in vitro modulation of cell signalling. (17th May 2013)

• Record Type: Journal Article
• Authors: Galougahi, Keyvan Karimi; Liu, Chia‐Chi; Garcia, Alvaro; Fry, Natasha A. S.; Hamilton, Elisha J.; Rasmussen, Helge H.; Figtree, Gemma A.
• Is Part Of: Journal of physiology. Volume 591:Number 12(2013:Jun.)
• Page Start: 2999
• Page End: 3015
• Publication Date: 2013-05-17
• Subjects: Physiology -- Periodicals; 612.005
• DOI: 10.1113/jphysiol.2013.252817
• Languages: English
• ISSNs: 0022-3751

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Key points</title> <p> <list id="l1" list-type="simple"> <list-item> <label> </label> <p>The widely believed effects of β<sub>1</sub> adrenergic receptors and protein kinase A (PKA) to stimulate the membrane Na<sup>+</sup>–K<sup>+</sup> pump in cardiac myocytes are not easily reconciled with the effects of activation of the receptor and PKA on contractility in normal heart or with the benefit of β<sub>1</sub> adrenergic blockade in heart failure.</p> </list-item> <list-item> <label> </label> <p>We show that reduction in PKA activity by β<sub>1</sub> adrenergic blockade <italic>in vivo</italic> stimulates the Na<sup>+</sup>–K<sup>+</sup> pump by reducing glutathionylation of one of its subunits, a reversible oxidative modification that inhibits pump activity.</p> </list-item> <list-item> <label> </label> <p>Na<sup>+</sup>–K<sup>+</sup> pump stimulation induced by β<sub>1</sub> adrenergic blockade <italic>in vivo</italic> is reversed by activation of PKA‐dependent signalling in isolated cardiac myocytes studied <italic>ex vivo</italic>.</p> </list-item> <list-item> <label> </label> <p>Inhibition of the myocyte Na<sup>+</sup>–K<sup>+</sup> pump mediated by PKA‐ and redox‐dependent signalling pathways and downstream glutathionylation of a subunit of the Na<sup>+</sup>–K<sup>+</sup> pump is readily reconciled with effects of PKA on contractility in normal heart and efficacy of β<sub>1</sub> adrenergic blockade in heart failure.</p> </list-item> </list> </p> <p> <bold>Abstract </bold> The widely reported stimulation of the cardiac Na<sup>+</sup>–K<sup>+</sup> pump by protein kinase A (PKA) should oppose other effects of PKA to increase contractility of the normal heart. It should also reduce harmful raised myocyte Na<sup>+</sup> levels in heart failure, yet blockade of the β<sub>1</sub> adrenergic receptor (AR), coupled to PKA signalling, is beneficial. We treated rabbits with the β<sub>1</sub> AR antagonist metoprolol to modulate PKA activity and studied cardiac myocytes <italic>ex vivo</italic>. Metoprolol increased electrogenic pump current (<italic>I</italic><sub>p</sub>) in voltage clamped myocytes and reduced glutathionylation of the β<sub>1</sub> pump subunit, an oxidative modification causally related to pump inhibition. Activation of adenylyl cyclase with forskolin to enhance cAMP synthesis or inclusion of the catalytic subunit of PKA in patch pipette solutions abolished the increase in <italic>I</italic><sub>p</sub> in voltage clamped myocytes induced by treatment with metoprolol, supporting cAMP/PKA‐mediated pump inhibition. Metoprolol reduced myocardial PKA and protein kinase C (PKC) activities, reduced coimmunoprecipitation of cytosolic p47<italic><sup>phox</sup></italic> and membranous p22<italic><sup>phox</sup></italic> NADPH oxidase subunits and reduced myocardial O<sub>2</sub><sup>−</sup>‐sensitive dihydroethidium fluorescence. Treatment also enhanced coimmunoprecipitation of the β<sub>1</sub> pump subunit with glutaredoxin 1 that catalyses de‐glutathionylation. Since angiotensin II induces PKC‐dependent activation of NADPH oxidase, we examined the effects of angiotensin‐converting enzyme inhibition with captopril. This treatment had no effect on PKA activity but reduced the activity of PKC, reduced β<sub>1</sub> subunit glutathionylation and increased <italic>I</italic><sub>p</sub>. The PKA‐induced Na<sup>+</sup>–K<sup>+</sup> pump inhibition we report should act with other mechanisms that enhance contractility of the normal heart but accentuate the harmful effects of raised cytosolic Na<sup>+</sup> in the failing heart. This scheme is consistent with the efficacy of β<sub>1</sub> AR blockade in the treatment of heart failure.</p> </abstract>